MSCs for Prevention of MI-induced HF
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 420 participants.
Also called NCT05043610
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 420 participants
- Registry
-
NCT05043610
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Iran
- Registry status
- Completed
Technical summary
Registry record NCT05043610. Randomized; single masking; primary purpose treatment. Start 2021-09-15 (actual); primary completion 2024-11-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- MSCs for Prevention of MI-induced HF
- Acronym
- PREVENT-TAHA8
- Condition
- Myocardial Infarction, Acute
- Condition
- Myocardial Infarction First
- Condition
- Myocardial Infarction, Anterior Wall
- Condition
- Cardiac Remodeling, Ventricular
- Condition
- STEMI
- Condition
- Regenerative Medicine
- Condition
- Heart Failure
- Intervention (Biological)
- Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs)
- Intervention (Other)
- Conventional Treatment
- Lead sponsor
- Shiraz University of Medical Sciences
- Collaborator
- National Institute for Medical Research and Development
Record details
- Record id
cardio:ct-nct05043610- Content hash
02a37aedac20b83efc46bbffb445d211abfe8e99b25d19087d6e1738ec178711